The Filing Desk

InnovAge

INNV · Nasdaq · Health Care · Financials, fiscal 2020 to 2026

INNV · Last close · November 19, 2026
$8.91
Value InnovAge yourself

InnovAge's revenue rose 15.9% to $990 million in fiscal 2026. Its operating margin was 0.3%, up from −3.5% a year earlier. Free cash flow was $50 million, up 89.5%. The diluted share count rose 0.2%.

InnovAge Holding Corp. Latest fiscal year ended June 30, 2026 10-K filed September 9, 2026 · 0001834376-26-000049 Updated
Revenue
$990M
15.9%
Operating margin
0.3%
3.8 pts
Net income
−$2M
 
Free cash flow
$50M
89.5%
Return on capital
0.7%
10.9 pts
Market cap
$1.2B
Nov 19 close
P/E
148.5x
On $0.06 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What InnovAge does

InnovAge runs health care centers for frail older adults, many of whom qualify for both Medicare and Medicaid. It does this through the Program of All-Inclusive Care for the Elderly, known as PACE. The program covers a wide range of services: in-home care, primary care, therapy, dental and mental health care, meals, activities, transportation and care management. The goal is to keep participants living at home as long as it is safe.

InnovAge is paid a set amount per participant, a model called capitated care, and it contracts directly with government payors such as Medicare and Medicaid. It has one reportable segment, PACE. Under its contracts it takes on the risk that the cost of care will be higher than the payment. As of June 30, 2026, it served approximately 8,230 participants and operated 20 centers in California, Colorado, Florida, New Mexico, Pennsylvania and Virginia.

The company is based in Denver, Colorado. It went public in March 2021.

Its biggest risks, as it describes them

  • Under its PACE contracts it takes on all the risk that care will cost more than it is paid.
  • It depends on Medicare and Medicaid, and cuts to funding or changes in the rules could hurt it.
  • Its growth plans, including opening centers and making acquisitions, may not work as expected.
  • Government rules for PACE and the yearly payment rates can change.
From InnovAge's annual report on Form 10-K, filed September 9, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

InnovAge lost money in fiscal 2026: a net loss of $2 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments184174103106141
Debt incl. finance leases8688837363
Net debt (negative means net cash)−98−86−20−33−78
Net debt to EBITDA−10.3x———−3.3x
Debt to equity0.3x0.3x0.3x0.3x0.3x
Interest coverage−1.7x−12.4x−5.7x−6.8x0.6x
Current ratio2.3x1.4x1.2x1.1x1.1x
Quick ratio2.3x1.4x1.2x1.1x1.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project InnovAge's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought InnovAge shares on the open market, and 2 insiders sold $92.7 million, $207,182 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 25, 2026Nicole DamatoChief Legal OfficerSold plan23,814$8.70$207,182Form 4
Sep 24, 2026Ignite Aggregator Lp10% ownerSold10,000,000$9.25$92.5 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score4 of 96 of 96 of 9
Rule of 405.1%14.9%21.0%
Altman Z''0.900.080.40
Accruals ratio2.8%−11.8%−12.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailFailFail
Share count didn't riseFailPassFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score4 of 96 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put InnovAge side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
InnovAgeFY2615.9%0.3%5.1%0.7%−3.3x6
Guardant HealthFY2532.9%−44.5%−23.7%−188.8%—4Compare
CorVelFY267.0%—11.5%———Compare
Pennant GroupFY2536.3%5.5%3.8%9.3%2.6x5Compare
Sotera HealthFY255.7%—12.8%6.7%—7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue567638699688764854990
Revenue growth—12.4%9.5%−1.5%11.0%11.8%15.9%
Gross profit——135101132154228
Research and development———————
Operating income51−12−4−49−23−303
Net income26−44−6−41−21−30−2
Diluted EPS (US$)0.19−0.36−0.05−0.30−0.16−0.22−0.02
Diluted shares (millions)135124136136136135136
Cash flow
Cash from operations44−82720−373365
Capital expenditure121838238614
Free cash flow32−25−11−3−452750
Dividends paid01000000
Share buybacks07800000
Acquisitions00002450
Stock-based compensation0245787
Balance sheet at fiscal year end
Cash and short-term investments113202184174103106141
Debt incl. finance leases218858688837363
Total assets410532556567548527557
Total liabilities302174202253248264289
Shareholders' equity101335332296269235236
Margins and ratios
Gross margin——19.4%14.7%17.3%18.0%23.0%
Operating margin9.0%−1.9%−0.6%−7.2%−3.0%−3.5%0.3%
Net margin4.6%−6.9%−0.9%−5.9%−2.8%−3.5%−0.3%
Free cash flow margin5.6%−3.9%−1.6%−0.5%−5.9%3.1%5.1%
Rule of 40 (growth + FCF margin)—8.5%8.0%−2.0%5.1%14.9%21.0%
Return on capital—−4.5%−1.5%−17.1%−7.7%−10.2%0.7%
Return on equity—−20.2%−2.0%−12.9%−7.5%−12.0%−1.1%
Return on assets—−9.3%−1.2%−7.2%−3.8%−5.6%−0.5%
Net debt to EBITDA1.7x—−10.3x———−3.3x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: InnovAge's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with InnovAge.